Systemic Treatment of Granuloma Faciale
This first-line protocol addresses systemic pharmacological management of Granuloma faciale (ICD-11 EF40.20 / ICD-10 L92.2).
Treatment approach
The protocol centres on systemic medication. A sulfonamide antibiotic is among the established primary agents, with several alternative systemic options also covered.
Full agent selection, dosing guidance, and the complete regimen are in the structured protocol.
References
DOI: 10.2340/00015555-2784
- Dapsone, also known as diaminodiphenyl sulfone (DDS) is a sulfonamide antibiotic commonly used for treatment of GF at a dose of 50–150 mg daily.
- Systemic dapsone therapy is usually well tolerated at a dose of 100 mg daily; however, severe side-effects may occur, patients should be well counseled and followed-up.
View source ↗